AU778834B2 - Fatty acid analogs for diagnosis of coronary artery disease - Google Patents
Fatty acid analogs for diagnosis of coronary artery disease Download PDFInfo
- Publication number
- AU778834B2 AU778834B2 AU42433/00A AU4243300A AU778834B2 AU 778834 B2 AU778834 B2 AU 778834B2 AU 42433/00 A AU42433/00 A AU 42433/00A AU 4243300 A AU4243300 A AU 4243300A AU 778834 B2 AU778834 B2 AU 778834B2
- Authority
- AU
- Australia
- Prior art keywords
- fatty acid
- radiolabeled fatty
- radioisotope
- radiolabeled
- sum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000004665 fatty acids Chemical class 0.000 title claims description 125
- 239000000194 fatty acid Substances 0.000 title claims description 123
- 235000014113 dietary fatty acids Nutrition 0.000 title claims description 120
- 229930195729 fatty acid Natural products 0.000 title claims description 120
- 208000029078 coronary artery disease Diseases 0.000 title claims description 10
- 238000003745 diagnosis Methods 0.000 title description 3
- 239000003446 ligand Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 230000007935 neutral effect Effects 0.000 claims description 10
- 229910052702 rhenium Inorganic materials 0.000 claims description 10
- 210000002216 heart Anatomy 0.000 claims description 8
- 229910052713 technetium Inorganic materials 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical group [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- 229910052733 gallium Inorganic materials 0.000 claims description 4
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052738 indium Inorganic materials 0.000 claims description 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000004165 myocardium Anatomy 0.000 abstract description 9
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 description 27
- 239000002184 metal Substances 0.000 description 21
- 230000002107 myocardial effect Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012216 imaging agent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000009920 chelation Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000012620 biological material Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 230000004129 fatty acid metabolism Effects 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- -1 alkyl carbon Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- VPYQMEOYEWOVKO-UHFFFAOYSA-N 3h-dithiole-3,5-diamine Chemical class NC1SSC(N)=C1 VPYQMEOYEWOVKO-UHFFFAOYSA-N 0.000 description 2
- TYYIOZHLPIBQCJ-UHFFFAOYSA-N 4-[1-(4-aminophenyl)-2,2,2-trichloroethyl]aniline Chemical compound C1=CC(N)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(N)C=C1 TYYIOZHLPIBQCJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003281 rhenium Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- NPCIWINHUDIWAV-UHFFFAOYSA-N 15-(4-iodophenyl)-3-methylpentadecanoic acid Chemical compound OC(=O)CC(C)CCCCCCCCCCCCC1=CC=C(I)C=C1 NPCIWINHUDIWAV-UHFFFAOYSA-N 0.000 description 1
- YAONEUNUMVOKNQ-UHFFFAOYSA-N 15-(4-iodophenyl)pentadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC1=CC=C(I)C=C1 YAONEUNUMVOKNQ-UHFFFAOYSA-N 0.000 description 1
- VOZDNCFKGOLECZ-BTVCFUMJSA-N 2-hydroxypropanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VOZDNCFKGOLECZ-BTVCFUMJSA-N 0.000 description 1
- XEFOHUNTIRSZAC-UHFFFAOYSA-N 2-methylpentadecanoic acid Chemical compound CCCCCCCCCCCCCC(C)C(O)=O XEFOHUNTIRSZAC-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- DYIZHKNUQPHNJY-UHFFFAOYSA-N oxorhenium Chemical compound [Re]=O DYIZHKNUQPHNJY-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 230000008448 thought Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12929899P | 1999-04-14 | 1999-04-14 | |
| US60/129298 | 1999-04-14 | ||
| PCT/US2000/010096 WO2000061196A2 (en) | 1999-04-14 | 2000-04-14 | Fatty acid analogs for diagnosis of coronary artery disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4243300A AU4243300A (en) | 2000-11-14 |
| AU778834B2 true AU778834B2 (en) | 2004-12-23 |
Family
ID=22439338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU42433/00A Ceased AU778834B2 (en) | 1999-04-14 | 2000-04-14 | Fatty acid analogs for diagnosis of coronary artery disease |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6437103B1 (enExample) |
| EP (1) | EP1173226B1 (enExample) |
| JP (1) | JP2003517457A (enExample) |
| AT (1) | ATE337020T1 (enExample) |
| AU (1) | AU778834B2 (enExample) |
| CA (1) | CA2366789C (enExample) |
| DE (1) | DE60030270T2 (enExample) |
| ES (1) | ES2269131T3 (enExample) |
| WO (1) | WO2000061196A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2374743T3 (es) * | 1995-12-01 | 2012-02-21 | Molecular Insight Pharmaceuticals, Inc. | Estereoisómeros de análogos de ácidos grasos para imagen de diagnóstico. |
| EP2963017A1 (en) * | 2002-03-11 | 2016-01-06 | Molecular Insight Pharmaceuticals, Inc. | Technetium-dipyridine complexes, and methods of use thereof |
| JP4951798B2 (ja) * | 2002-04-01 | 2012-06-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 側基脂肪酸撮像剤 |
| MXPA05011189A (es) * | 2003-04-17 | 2006-05-25 | Gen Hospital Corp | Metodo para monitorear el flujo sanguineo y la captacion metabolica en el tejido con acido alcanoico radiomarcado. |
| KR100533674B1 (ko) * | 2004-02-25 | 2005-12-06 | 한국원자력연구소 | 수소화붕소 교환수지를 이용한 레늄 착물의 제조방법 |
| ES2380680T3 (es) * | 2005-06-08 | 2012-05-17 | Ge Healthcare Limited | Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcaje interno de ésteres marcados con 11C mediante carbonilación fotoinducida de radicales libres sensitizados |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4524059A (en) * | 1983-01-28 | 1985-06-18 | The General Hospital Corporation | Fatty acid analogs |
| US4615876A (en) * | 1983-04-25 | 1986-10-07 | Curators Of The University Of Missouri | Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides |
| US4746505A (en) | 1985-04-26 | 1988-05-24 | President And Fellows Of Harvard College | Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands |
| ES2374743T3 (es) * | 1995-12-01 | 2012-02-21 | Molecular Insight Pharmaceuticals, Inc. | Estereoisómeros de análogos de ácidos grasos para imagen de diagnóstico. |
-
2000
- 2000-04-14 AT AT00922209T patent/ATE337020T1/de not_active IP Right Cessation
- 2000-04-14 ES ES00922209T patent/ES2269131T3/es not_active Expired - Lifetime
- 2000-04-14 EP EP00922209A patent/EP1173226B1/en not_active Expired - Lifetime
- 2000-04-14 US US09/549,732 patent/US6437103B1/en not_active Expired - Fee Related
- 2000-04-14 CA CA2366789A patent/CA2366789C/en not_active Expired - Fee Related
- 2000-04-14 WO PCT/US2000/010096 patent/WO2000061196A2/en not_active Ceased
- 2000-04-14 AU AU42433/00A patent/AU778834B2/en not_active Ceased
- 2000-04-14 JP JP2000610528A patent/JP2003517457A/ja active Pending
- 2000-04-14 DE DE60030270T patent/DE60030270T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2366789C (en) | 2010-09-28 |
| US6437103B1 (en) | 2002-08-20 |
| DE60030270D1 (de) | 2006-10-05 |
| DE60030270T2 (de) | 2007-08-30 |
| WO2000061196A2 (en) | 2000-10-19 |
| JP2003517457A (ja) | 2003-05-27 |
| ES2269131T3 (es) | 2007-04-01 |
| EP1173226B1 (en) | 2006-08-23 |
| AU4243300A (en) | 2000-11-14 |
| EP1173226A2 (en) | 2002-01-23 |
| ATE337020T1 (de) | 2006-09-15 |
| CA2366789A1 (en) | 2000-10-19 |
| WO2000061196A3 (en) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4925650A (en) | Technetium -99m complex for examining the renal function | |
| AU2020262961B2 (en) | Prostate-specific membrane antigen (PSMA) inhibitors as diagnostic and radionuclide therapeutic agents | |
| Kung | New technetium 99m-labeled brain perfusion imaging agents | |
| Volkert et al. | Technetium-99m chelates as radiopharmaceuticals | |
| Oya et al. | Small and neutral TcvO BAT, bisaminoethanethiol (N2S2) complexes for developing new brain imaging agents | |
| US5986074A (en) | Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof | |
| AU2004210208B2 (en) | Diagnostic imaging agents with MMP inhibitory activity | |
| Choi et al. | An improved kit formulation of a dopamine transporter imaging agent:[Tc-99m] TRODAT-1 | |
| AU778834B2 (en) | Fatty acid analogs for diagnosis of coronary artery disease | |
| NZ263794A (en) | Compound suitable for forming tc and re chelates, radiopharmaceutical compositions thereof | |
| JPH06502640A (ja) | テクネチウム−９９ｍ錯化合物の放射性医薬としての使用 | |
| JP4338394B2 (ja) | テクネチウム−９９ｍ窒化物ヘテロ錯体を含有する放射性画像診断剤 | |
| US5876693A (en) | Hydroxyalkyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals | |
| JP3935218B2 (ja) | 放射性遷移金属窒化物へテロ錯体 | |
| JPH06501450A (ja) | シクロペンタジエニルカルボニル―９９ｍＴｃ錯体、その製造法および診断学への該化合物の使用 | |
| Ohmomo et al. | New conformationally restricted technetium-99m N2S2 complexes as myocardial perfusion imaging agents | |
| Kothari et al. | Syntheses, in vitro and in vivo characterization of a 99mTc-(I)-tricarbonyl-benzylamino-dihydroxymethyl phosphine (NP2) chelate | |
| Cazzola et al. | Labeling of fatty acid ligands with the strong electrophilic metal fragment [99mTc (N)(PNP)] 2+(PNP= diphosphane ligand) | |
| Zhuang et al. | Neutral and stereospecific Tc-99m complexes:[99mTc] N-benzyl-3, 4-di-(N-2-mercaptoethyl)-amino-pyrrolidines (P-BAT) | |
| Blau | Radiotracers for functional brain imaging | |
| Eckelman et al. | Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution | |
| JP2564459B2 (ja) | 放射性医薬品調製用キャリヤー | |
| US20040087567A1 (en) | Diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition | |
| John et al. | Preparation, radiolabeling and biodistribution of a new class of bisaminothiol (BAT) ligands as possible imaging agents | |
| Verbruggen | Bifunctional chelators for technetium-99m |